Scholar Rock Holding Corporation (SRRK)

9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)